4-cyclohexyl-1-(4-methylphenyl)butan-1-one | 180136-25-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-cyclohexyl-1-(4-methylphenyl)butan-1-one
• CAS: 180136-25-8
• 化学式: C₁₇H₂₄O
• 分子量: 244.377
• InChiKey: MPQOCKALDALYJP-UHFFFAOYSA-N

物化性质

• 沸点：
  363.1±11.0 °C(Predicted)
• 密度：
  0.966±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-cyclohexyl-1-(4-methylphenyl)butan-1-one 在 palladium on activated charcoal 硫酸 、 氢气 、 硝酸 作用下， 以 乙醇 为溶剂， -7.0~25.0 ℃ 、101.33 kPa 条件下， 反应 16.33h， 生成 4-cyclohexyl-1-(3-amino-4-methylphenyl)butan-1-one
  参考文献：
  名称：

  New Low-Density Lipoprotein Receptor Upregulators Acting via a Novel Mechanism

  摘要：

  The synthesis and biological activity of a new series of benzamides and related compounds that upregulate the expression of the low-density lipoprotein (LDL) receptor in human hepatocytes (HepG2 cells) by a novel mechanism are described. The lead compound, N-[5-[(3-cyclohexylpropionyl)amino]-2-methylphenyl]-4-hydroxybenzamide (1, RPR102359), increased the expression of the LDL receptors in HepG2 cells by 80% when tested at a concentration of 3 mu M. Mevinolin (lovastatin) was found to increase the LDL receptor expression by 70% at the same concentration. In contrast to mevinolin, 1 was found to have no effect on cholesterol biosynthesis in liver homogenates or in HepG2 cells at doses where substantial upregulation of the LDL receptor was observed and thus stimulated LDL receptor expression by a novel mechanism.

  DOI：

  10.1021/jm960153q
• 作为产物：
  描述：

  环已烷丁酸 在 三氯化铝 、 氯化亚砜 作用下， 反应 57.5h， 生成 4-cyclohexyl-1-(4-methylphenyl)butan-1-one
  参考文献：
  名称：

  New Low-Density Lipoprotein Receptor Upregulators Acting via a Novel Mechanism

  摘要：

  The synthesis and biological activity of a new series of benzamides and related compounds that upregulate the expression of the low-density lipoprotein (LDL) receptor in human hepatocytes (HepG2 cells) by a novel mechanism are described. The lead compound, N-[5-[(3-cyclohexylpropionyl)amino]-2-methylphenyl]-4-hydroxybenzamide (1, RPR102359), increased the expression of the LDL receptors in HepG2 cells by 80% when tested at a concentration of 3 mu M. Mevinolin (lovastatin) was found to increase the LDL receptor expression by 70% at the same concentration. In contrast to mevinolin, 1 was found to have no effect on cholesterol biosynthesis in liver homogenates or in HepG2 cells at doses where substantial upregulation of the LDL receptor was observed and thus stimulated LDL receptor expression by a novel mechanism.

  DOI：

  10.1021/jm960153q

文献信息

• New Low-Density Lipoprotein Receptor Upregulators Acting <i>via</i> a Novel Mechanism
  作者：Michael J. Ashton、Thomas J. Brown、Garry Fenton、Frank Halley、Mark F. Harper、Peter M. Lockey、Barry Porter、Alan G. Roach、Keith A. J. Stuttle、Nigel Vicker、Roger J. A. Walsh

  DOI：10.1021/jm960153q

  日期：1996.1.1

  The synthesis and biological activity of a new series of benzamides and related compounds that upregulate the expression of the low-density lipoprotein (LDL) receptor in human hepatocytes (HepG2 cells) by a novel mechanism are described. The lead compound, N-[5-[(3-cyclohexylpropionyl)amino]-2-methylphenyl]-4-hydroxybenzamide (1, RPR102359), increased the expression of the LDL receptors in HepG2 cells by 80% when tested at a concentration of 3 mu M. Mevinolin (lovastatin) was found to increase the LDL receptor expression by 70% at the same concentration. In contrast to mevinolin, 1 was found to have no effect on cholesterol biosynthesis in liver homogenates or in HepG2 cells at doses where substantial upregulation of the LDL receptor was observed and thus stimulated LDL receptor expression by a novel mechanism.